The pres, does mention it
"Sozinibercept is being developed for use in combination with any of the existing anti-VEGF-A agents, biosimilars, or novel therapies in development for wAMD...The $15bn global market comprised of Eylea, Vabysmo, Lucentis revenue plus an estimate for biosimilars, Avastin off-label, and Beovu of ~$1bn"
Ann: Trading Halt, page-119
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $398.3M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 38.5¢ | 35.5¢ | $685.8K | 1.856M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 61550 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 48038 | 9 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |